Breakthrough
Peptide
Technology

Hybridtides® are a new class of drug candidates that deliver unique product profiles.

Preclinical Development

Longevity Biotech has multiple preclinical programs in development all based on the Hybridtide® core technology.

Pipeline

Oral Peptide Delivery

Hybridtides® demonstrate robust durability in a variety of biological matrices. Absorption parameters are optimized via our proprietary databases.

Artistan Biology®

The unique composition of Hybridtides® (natural and non-natural amino acids) enables 'fine-tuning' of intracellular signal cascades. In other words, Hybridtides® demonstrate signal bias.

0
Peer Reviewed Papers

0
Citations

0
Patents

0
Preclinical Programs

0
Purpose

Contact Us

Email

Info@LongevityBiotech.com


Office

3624 Market Street
Philadelphia, PA 19104


Phone

215.689.1042

Investors & Support


  • Breakout Labs
  • NetSci
  • MJFF
  • NSF

Contact us today to learn how you can help support our development efforts.

Developing breakthrough therapeutics based on the Hybridtide® peptide scaffold

Platform Collaboration

HOT

Hybridtide Optimization Toolkit

If your preclinical peptide program requires demonstrated market leading stability in any biological environment – without compromising functionality – contact us, Hybridtides® can deliver your product profile.


Oral Peptide Platform

Formulation alone is not sufficient for commercial success, API’s require a combination of stability, solubility and absorption. Our team can evaluate your program across these critical parameters (in vitro and in vivo) and can help optimize your program along these critical dimensions for oral delivery.


Artisan Biology

Hybridtides can modulate molecular biology pathways (e.g. cAMP, β-Arrestin1 & β-Arrestin2) independent of each other in addition to targeting different states of a protein (e.g. open vs. closed). These features are critical for intracellular targeting, delivery or binding affinity tuning. Contact us to learn more.